Gilvetmab

Last updated April 04, 2019

Gilvetmab
Monoclonal antibody
Type	?
Source	Mouse
Target	PCDC1
Clinical data
Synonyms	PD1
ATC code	none
Identifiers
CAS Number	1808081-43-7
ChemSpider	none
UNII	949NG8376D
Chemical and physical data
Formula	C₆₅₇₈H₁₀₂₁₂N₁₇₆₆O₂₀₂₃S₄₈
Molar mass	147.9 g/mol

Gilvetmab (INN ^[1]) (PD1) is a veterinary monoclonal antibody.

This drug was developed by Merck Sharp & Dohme Corp.^[2]

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world.

References

↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Gilvetmab, American Medical Association.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression : Abrilumab Adalimumab Anifrolumab ^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab ^† Fresolimumab Gimsilumab Golimumab Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Sarilumab Sifalimumab Tabalumab Tezepelumab ^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab ^† Urelumab Other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Andecaliximab ^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab ^§ Benralizumab Cedelizumab Certolizumab pegol Crizanlizumab ^† Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab ^† Fontolizumab Inebilizumab ^† Itolizumab Lampalizumab ^† Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 ^† Quilizumab Ravulizumab ^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Siplizumab Talizumab Teplizumab Tibulizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 ^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized ("-lixizu-")	Otelixizumab Tavolimab
Veterinary ("-lvet-")	Gilvetmab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab ^† Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab ^† Perakizumab Risankizumab ^† Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab ^‡ Lemalesomab Sulesomab

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.